CD274 and neoplasm: According to a biomarker sub-study of the IMpassion130 trial both tumor and immune cell PD-L1 expression were predictive for immune check point therapy benefit, but the predictive impact of immune cell expression was stronger, and in multivariate analyses tumor cell PD-L1 expression was no longer significant in addition to immune cell expression [40].